Journal Logo

You can read the full text of this article if you:

Institutional members access full text with Ovid®

Clinical Investigations

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Froissart, Antoine MD; Buffet, Marc MD; Veyradier, Agnès MD, PhD; Poullin, Pascale MD; Provôt, François MD; Malot, Sandrine RN; Schwarzinger, Michael PhD; Galicier, Lionel MD; Vanhille, Philippe MD; Vernant, Jean-Paul MD; Bordessoule, Dominique MD; Guidet, Bertrand MD; Azoulay, Elie MD, PhD; Mariotte, Eric MD; Rondeau, Eric MD; Mira, Jean-Paul MD, PhD; Wynckel, Alain MD; Clabault, Karine MD; Choukroun, Gabriel MD, PhD; Presne, Claire MD; Pourrat, Jacques MD; Hamidou, Mohamed MD; Coppo, Paul MD, PhD

Author Information
doi: 10.1097/CCM.0b013e31822e9d66
  • Buy
  • SDC

© 2012 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins